Beam Therapeutics Inc. (BEAM) News
Filter BEAM News Items
BEAM News Results
|Loading, please wait...|
BEAM News Highlights
- For BEAM, its 30 day story count is now at 7.
- Over the past 24 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BASE, AAT and CELL are the most mentioned tickers in articles about BEAM.
Latest BEAM News From Around the Web
Below are the latest news stories about BEAM THERAPEUTICS INC that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
The iconic money manager has struggled the last two months. Let's see what she's buying to get back on track.
Despite a sizzling start to the year, growth stocks have suddenly found themselves on the outs with investors. Concerns about the global economy, persistently high interest rates, and stubborn levels of inflation have weighed heavily on pure-play growth stocks in the second half of the year. Biotechnology stocks have taken a particularly hard hit over this period.
Warren Buffett has been a net seller of stocks in recent months, but it's a different story for Cathie Wood. If you're an aggressive investor, here are three stocks that Wood is buying that should be on your list, too. Wood's flagship Ark Innovation ETF added to its existing position in Beam Therapeutics (NASDAQ: BEAM) over the last several weeks.
Beam Therapeutics' (NASDAQ: BEAM) stock has fallen by 40% this year so far, but that hasn't stopped portfolio manager Cathie Wood's ARK Genomic Revolution ETF from loading up on its shares. Now, the stock accounts for nearly 2% of the ARK Invest portfolio of exchange-traded funds (ETFs). Cathie Wood is unlikely to harbor any illusions about Beam Therapeutics as it exists today.
A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team.
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
First Preclinical Data for BEAM-302 Demonstrate Increased Levels of Corrected AAT and Reduced Mutant PiZ AAT in Multiple In Vivo Rodent Disease ModelsCAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in vivo drug candidate, BEAM-302, to directly correct the PiZ mutation, the primary disease-causing muta
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therap
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston;2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 at 10:15 a.m. ET
Cathie Wood is one of the most influential investors in the world. ARK Invest manages several exchange-traded funds (ETFs) that have delivered stellar returns for investors in 2023. Beam Therapeutics (NASDAQ: BEAM), COMPASS Pathways (NASDAQ: CMPS), and 908 Devices (NASDAQ: MASS) are three ARK Invest holdings with strong buy ratings and exceptionally high price targets from the analysts who cover them.
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good.